Tris Pharma

Tris Pharma is a pharmaceutical company focused on developing and delivering treatments for ADHD, pain, addiction, and other diseases of the central nervous system. Its mission is to address difficult therapeutic challenges through innovative approaches designed to meet patients’ needs. The company emphasizes high-quality, patient-friendly medicines intended to provide meaningful benefits and improve the treatment experience for adults and children.

Tris Pharma has developed a portfolio of four leading ADHD therapies and uses its proprietary LiquiXR technology to support the development of medicines and investigational programs. The technology has powered more than a dozen medicines and programs, according to the company. Beyond its marketed medicines, Tris Pharma maintains a pipeline of investigational therapies for ADHD, pain, addiction, and other central nervous system disorders. Its work includes research and development, clinical publications, and partnerships, alongside engagement with patient advocacy groups and scientific advisors. Based in Monmouth Junction, New Jersey, Tris Pharma presents innovation, individualized care, and a commitment to patients as central to its work.